Evaluating Pharmacogenomic Variants for Cardiology Therapeutics: the Lighthouse Pilot (Association Between Genetic Variant Scores and P2Y12 Inhibitor Effects)
Status: Completed
Location: See location...
Intervention Type: Diagnostic test
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY
Cipherome's Lighthouse is a clinical decision support tool that incorporates a patient's pharmacogenetic information to determine therapeutic strategy, including determining appropriate dosage or assessing the likelihood of toxicity of a therapeutic regimen.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 99
Healthy Volunteers: f
View:
• Subjects over 18 years of age, who are:
• On clopidogrel, prasugrel or ticagrelor after percutaneous stent
• Completed informed consent
Locations
United States
Texas
Doctors Hospital at Renaissance
Edinburg
Time Frame
Start Date: 2020-12-03
Completion Date: 2023-07-27
Participants
Target number of participants: 300
Treatments
No_intervention: Conventional Therapy (Controls)
Treatment with clopidogrel and no pre-emptive genotyping
Experimental: Genotype-guided therapy (experimental)
1. Treatment with clopidogrel 75 mg daily for non-carriers~2. Treatment with ticagrelor 90 mg twice daily for carriers
Authors
Humberto Mochizu Kitamayo, Herschl Silberman
Related Therapeutic Areas
Sponsors
Leads: Cipherome, Inc.
Collaborators: DHR Health Institute for Research and Development